Endocrine-Related Cancer

Article	Citations
Acknowledgement to reviewers	98
Refining long-term surveillance requirements in patients with differentiated thyroid cancer	82
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression	61
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	51
Acknowledgement to reviewers	45
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	45
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	44
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	39
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	38
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	38
Update on the genetics of paragangliomas	31
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	31
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	31
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	30
Targeting growth hormone in cancer: future perspectives	30
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	30
Survival following resection of 10,244 lung neuroendocrine tumours: a population study	30
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	26
Radioiodine treatment: an historical and future perspective	26
Metabolically active brown adipose tissue in PPGL: an observational cohort study	26
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	25
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	24
Peptide receptor radionuclide therapy in malignant insulinoma	24
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	23
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation	23

Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	23
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	23
Antitumor immune response is associated with favorable survival in GEP-NEN G3	22
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	22
Gender-affirming care and endocrine-related cancers	21
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	21
Whole-exome sequencing of rectal neuroendocrine tumors	21
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia	20
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	20
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	20
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	18
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	17
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	16
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	15
Effect of TSH levels during active surveillance of PTMC according to age	15
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	14
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	14
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	14
From bench to bedside in the sella: translational developments in pituitary tumour genetics	14
Immunotherapy for endocrine tumours: a clinician’s perspective	14
Exploring stem cell biology in pituitary tumors and derived organoids	14
Acknowledgement to reviewers	13
Steroid profile in patients with breast cancer and in mice treated with mifepristone	13
Clinical features of plurihormonal pituitary adenoma subtypes	13
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	13
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	13
Acknowledgement to reviewers	13
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	13
New therapeutic opportunities for women with low-grade serous ovarian cancer	12
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	12
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	12
Inhibition of GATA2 in prostate cancer by a clinically available small molecule	12
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer	12
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	12
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma	12
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	11
Systems biology successes and areas for opportunity in prostate cancer	11
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	11
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	11
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	11
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	11
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	11
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	11
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	11
Genetic disorders and insulinoma/glucagonoma	11
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	11
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	11
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	11
Deiodinases in thyroid tumorigenesis	10
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms	10

Mendelian randomization to investigate the link between TSH and thyroid cancer	10
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	10
Non-pituitary GH regulation of the tissue microenvironment	10
Beyond the three P’s: adrenal involvement in MEN1	10
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	10
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	10
In memoriam: Charis Eng MD PhD (1962–2024)	9
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	9
MicroRNAs as regulators of tumor metabolism	9
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	9
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	9
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	9
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	9
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	9
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	9
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms	9
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	9
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	8
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	8
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	8
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	8
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	8
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	8
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	8
Surrogate molecular classification of LAR breast cancer in routine workflow	8
Precocious puberty due to intracranial germ cell tumors: a case–control study	8
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	8
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	8
Risk factors for intraoperative complications in pheochromocytomas	7
Exploring chromosomal instability and clonal heterogeneity in breast cancer	7
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	7
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination	7
Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis	7
A clinically applicable molecular classification of oncocytic cell thyroid nodules	7
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer	7
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	7
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents	7
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy	7
Predictors of cancer in patients with endogenous Cushing’s syndrome	7
Endocrine cancer trends 1990–2021: global disparities and health inequalities	7
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	7
Insulinomatosis: new aspects	7
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	7
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature	7
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	7
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	6
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	6
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer	6
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	6
Inflammation-based score in pediatric adrenocortical carcinoma	6
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	6
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	6
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	6
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix	6
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	6
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	6
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	6
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	5
Pituitary tumor-transforming gene 1 and endocrine cancers: an up-to-date review through history, current insights and future perspectives	5
Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?	5
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	5
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	5
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	5
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	5
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	5
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	5
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	5
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	5
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	5
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	5
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	5
Progress and challenges in experimental models for pheochromocytoma and paraganglioma	5
Improved and individualized approach to adrenal surgery	4
Development and validation of long-acting recombinant human TSH using SAFA technology	4
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	4
Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma	4
Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer	4
β-Catenin activation and illicit receptor expression in adrenocortical cells	4
Pregnancy-associated breast cancer: the influence of gestational age	4

NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	4
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	4
Mechanisms of resistance to RET-directed therapies	4
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	4
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	4
Autocrine/paracrine growth hormone in cancer progression	4
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	4
Therapeutic inhibition of ATR in differentiated thyroid cancer	4
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	4
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study	4
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?	4
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells	4
The role of membrane mucin MUC4 in breast cancer metastasis	4
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?	4
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	4
Second primary cancers and survival among neuroendocrine tumor patients	4
Aggressive versus indolent insulinomas: new clinicopathological insights	3
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	3
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	3
Growth hormone and radiation therapy: friend, foe, or both?	3
Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era	3
Oxygen regulates proliferation and phenotype in the RS0 SDH-deficient pheochromocytoma cell line	3
Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors	3
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients	3
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	3
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis	3
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	3
Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer	3
The role of vitamin D in breast cancer risk and progression	3
Heme-oxygenase-1: a key player in thyroid carcinoma development	3
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	3
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	3
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	3
FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients	3
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	3
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	3
Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms	3
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 2021	3